INPP5E

The INPP5E gene tells cells how to make an enzyme that adjusts the phospholipid (fatty membrane) composition of the primary cilium. The primary cilium acts like a cellular antenna that receives and passes on signals. In photoreceptors — the cells in the retina that capture light — a specialized cilium connects the parts of the cell and helps build and maintain the light-sensing outer segment. When INPP5E does not work properly, cilia can be shortened or dysfunctional, which is why conditions caused by this gene are called ciliopathies. INPP5E is historically associated with Joubert Syndrome, a ciliopathy (definition: A disease caused by a problem with cilia — tiny hair-like structures on cells, including the light-sensing cells in the retina, that the cell needs to work properly.) defined by a midbrain-hindbrain malformation that can also include retinal dystrophy, kidney disease (nephronophthisis), liver fibrosis, and extra fingers or toes (polydactyly). Not everyone with an INPP5E variant has all of these features.

Researchers have reported a range of retinal presentations linked to INPP5E variants. In studies of families with retinal degeneration but no full syndrome, some people were classified as having LCA (a severe, early-onset loss of vision), while others had a milder, later-onset rod-cone dystrophy (a gradual loss of night and peripheral vision followed by central vision). A small number showed mild ciliopathy (definition: A disease caused by a problem with cilia — tiny hair-like structures on cells, including the light-sensing cells in the retina, that the cell needs to work properly.) features that resolved in childhood. Other reports describe non-syndromic retinitis pigmentosa confirmed with laboratory cell testing. The same gene, when causing Joubert Syndrome, can involve retinal dystrophy alongside neurological and other organ features. Because presentations vary so widely, an INPP5E result does not by itself predict how any one person's vision will change over time.

It is well established that INPP5E encodes a ciliary enzyme important for the membrane composition of primary cilia and photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cilia. Multiple human studies have linked biallelic (both-copy) INPP5E variants to Joubert Syndrome and, more recently, to non-syndromic inherited retinal degeneration. Two independent human cohort studies reported novel INPP5E variants in families with retinal disease and expanded the recognized range of INPP5E-related conditions. Laboratory work in patient cells and human retinal organoids (lab-grown mini-retinas) shows that loss of INPP5E disrupts cilia and affects photoreceptor outer segment formation, and mouse studies show that removing INPP5E from the retina causes a rapid rod-cone degeneration resembling LCA. Together these lines of evidence support INPP5E as a genuine cause of retinal degeneration.

A clear relationship between which INPP5E variants a person carries and how severe their disease will be (a genotype (definition: A person's specific genetic makeup — which gene and which variant is causing their condition — as opposed to the phenotype, the symptoms it produces.)-phenotype (definition: The observable traits or symptoms a condition actually produces in a person — as opposed to the genotype, the underlying genetic cause.) correlation) has not been established; researchers suggest other genetic modifiers may influence the outcome. The number of reported non-syndromic retinal cases remains relatively small, and some findings come from laboratory cell and animal models rather than large patient studies. It is not possible from the available evidence to predict age of onset, rate of progression, or whether systemic (non-eye) features will appear in an individual. Some reports involve single patients or variants of uncertain significance, which need cautious interpretation.

RP Hope's reviewed records do not currently identify a gene-specific approved treatment for INPP5E-related retinal disease. Current research is largely focused on understanding how INPP5E dysfunction damages photoreceptors. For example, using human retinal organoids and patient-derived cells to study cilia, outer segment formation, and interacting proteins such as EHBP1, and using mouse models to trace how loss of INPP5E disrupts the photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cilium. These are laboratory and animal studies that build scientific understanding; they are not treatments available to patients. Some studies also describe how INPP5E interacts with proteins involved in other retinal diseases (such as RPGR and PDE6D), which helps map the shared biology of ciliary retinal disorders.

• Using cilia testing to confirm INPP5E variants cause RP

  Human case study with laboratory cell functional testing.

  What was found:

  Both patients' cells showed shorter cilia and loss of INPP5E localization within the cilium, functionally confirming the variants as the cause of their RP.

  Why it matters:

  It shows how laboratory cilia testing can help confirm whether uncertain INPP5E variants are disease-causing.

  Limitation: Only two patients; laboratory assay rather than large clinical cohort.

• How losing INPP5E harms photoreceptors (lab organoid model)

  Laboratory research in human stem-cell-derived organoids.

  What was found:

  INPP5E is important in early retinal development; without it, key proteins mislocalize and photoreceptor outer segment membranes become elongated in both rods and cones, pointing to a role in outer segment membrane biogenesis.

  Why it matters:

  It clarifies the cellular mechanism by which INPP5E loss damages the human retina.

  Limitation: A lab model, not a study of patients or a treatment.

• Mouse retina without INPP5E develops LCA-like degeneration

  Preclinical animal (mouse) study.

  What was found:

  These mice developed a rapid rod-cone degeneration resembling Leber congenital amaurosis; photoreceptor axoneme and disc membranes failed to form, with disrupted intraflagellar transport.

  Why it matters:

  It supports a direct, causal role for INPP5E in building and maintaining photoreceptors.

  Limitation: Findings in mice may not fully match human disease and do not represent a treatment.

• INPP5E can cause retinal degeneration without the full syndrome

  Observational human genotype-phenotype study (preprint).

  What was found:

  Fourteen rare INPP5E variants (12 novel) were found. Retinal disease ranged from Leber congenital amaurosis in four probands to a milder, later-onset rod-cone dystrophy in eight; two had mild ciliopathy features that resolved in childhood. No clear genotype-phenotype correlation emerged.

  Why it matters:

  It expands the recognized spectrum of INPP5E disease to include early-onset, previously underdiagnosed non-syndromic retinal degeneration.

  Limitation: Small number of families, preprint status, and no clear variant-to-severity relationship.

• Confirming INPP5E in non-syndromic retinal disease across more families

  Observational human genotype-phenotype study.

  What was found:

  Sixteen non-syndromic IRD patients plus two with early-onset IRD and limited Joubert features were described, with 14 rare variants (12 novel). Again, no clear genotype-phenotype correlation was seen, suggesting genetic modifiers.

  Why it matters:

  It provides independent confirmation that INPP5E variants can lead to retinal degeneration without the wider syndrome.

  Limitation: Modest cohort size and unexplained variability in severity.

Caregivers can offer the most helpful support by first asking the person what kind of assistance, if any, they prefer, and respecting their independence. Because INPP5E-related retinal conditions vary widely, needs differ from person to person. Practical areas that may be worth exploring together include low-vision rehabilitation, accessible technology, transportation options, and school or workplace accommodations. Emotional and community support matters too. Reading others' first-person accounts can help families feel less alone. For questions about inheritance and testing of relatives, genetic counseling is a good resource.

• Do my specific INPP5E variants appear to explain a non-syndromic retinal condition, or is there reason to evaluate for wider ciliopathy features?
• Given the wide range described for INPP5E, what type and severity of retinal disease best matches my clinical findings?
• Would any monitoring of kidney, liver, or neurological health be reasonable in my situation?
• What retinal tests could help track how my vision changes over time?
• What does this result mean for my children or other relatives, and would genetic counseling be helpful?
• Are there low-vision or rehabilitation services you would recommend now?

A confirmed genetic result is often most useful when reviewed with a retinal specialist and a genetic counselor, who can interpret the specific variants, discuss whether any monitoring for systemic features associated with ciliopathies may be appropriate, and explain what the result may mean for family members. Genetic counseling can also clarify inheritance patterns. RP Hope's resources on genetic testing and its guided pathway can help you prepare for these conversations.